Literature DB >> 23969188

Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers.

Carol Li1, Patricia Aragon Han, Kathleen C Lee, Louis C Lee, Amy C Fox, Toni Beninato, Michele Thiess, Benzon M Dy, Thomas J Sebo, Geoffrey B Thompson, Clive S Grant, Thomas J Giordano, Paul G Gauger, Gerard M Doherty, Thomas J Fahey, Justin Bishop, James R Eshleman, Christopher B Umbricht, Eric B Schneider, Martha A Zeiger.   

Abstract

BACKGROUND: Existing evidence is controversial regarding the association between BRAF mutation status and aggressive features of papillary thyroid cancer (PTC). Specifically, no study has incorporated multiple surgical practices performing routine central lymph node dissection (CLND) and thus has patients who are truly evaluable for the presence or absence of central lymph node metastases (CLNMs).
METHODS: Consecutive patients who underwent total thyroidectomy and routine CLND at 4 tertiary endocrine surgery centers were retrospectively reviewed. Descriptive and bivariable analyses examined demographic, patient, and tumor-related factors. Multivariable analyses examined the odds of CLNM associated with positive BRAF status.
RESULTS: In patients with classical variant PTC, bivariate analysis found no significant associations between BRAF mutation and aggressive clinicopathologic features; multivariate analysis demonstrated that BRAF status was not an independent predictor of CLNM. When all patients with PTC were analyzed, including those with aggressive or follicular subtypes, bivariate analysis showed BRAF mutation to be associated with LNM, advanced American Joint Committee on Cancer (AJCC) stage, and histologic subtype. Multivariable analyses showed BRAF, age, size, and extrathyroidal extension to be associated with CLNM.
CONCLUSION: Although BRAF mutation was found to be an independent predictor of central LNM in the overall cohort of patients with PTC, this relationship lost significance when only classical variant PTC was included in the analysis. The usefulness of BRAF in predicting the presence of LNM remains questionable. Prospective studies are needed before BRAF mutation can be considered a reliable factor to guide the treatment of patients with PTC, specifically whether to perform prophylactic CLND.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23969188     DOI: 10.1210/jc.2013-1584

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

1.  BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice?

Authors:  Efisio Puxeddu; Sebastiano Filetti
Journal:  Endocrine       Date:  2013-12-24       Impact factor: 3.633

2.  Loss of CPSF2 expression is associated with increased thyroid cancer cellular invasion and cancer stem cell population, and more aggressive disease.

Authors:  Naris Nilubol; Myriem Boufraqech; Lisa Zhang; Electron Kebebew
Journal:  J Clin Endocrinol Metab       Date:  2014-03-21       Impact factor: 5.958

3.  Ultrasonography, FNA, mutations, hormones and thyroid nodule obsession in the twenty-first century: a cytopathologist's plea for reason in the age of thyroid storm.

Authors:  Vicki J Schnadig
Journal:  Endocrine       Date:  2014-06-13       Impact factor: 3.633

4.  RAS/BRAF mutational status in familial non-medullary thyroid carcinomas: A retrospective study.

Authors:  Matteo Landriscina; Maria Iole Natalicchio; Olga Lamacchia; Antonella Conserva; Annamaria Piscazzi; Anna Ciampolillo; Matteo Zingrillo; Antonio Pennella; Pantaleo Bufo; Giulia Vita; Raffaele Antonetti; Eugenio Maiorano; Francesco Giorgino; Mauro Cignarelli
Journal:  Oncol Lett       Date:  2015-06-17       Impact factor: 2.967

5.  Targeted next-generation sequencing of cancer-related genes in thyroid carcinoma: A single institution's experience.

Authors:  Nobuyuki Bandoh; Toshiaki Akahane; Takashi Goto; Michihisa Kono; Haruyuki Ichikawa; Takahiro Sawada; Tomomi Yamaguchi; Hiroshi Nakano; Yumiko Kawase; Yasutaka Kato; Hajime Kamada; Yasuaki Harabuchi; Kazuo Shimizu; Hiroshi Nishihara
Journal:  Oncol Lett       Date:  2018-10-02       Impact factor: 2.967

6.  Frequent BRAF V600E and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan.

Authors:  Naoki Oishi; Tetsuo Kondo; Tadao Nakazawa; Kunio Mochizuki; Tomohiro Inoue; Kazunari Kasai; Ippei Tahara; Tomonori Yabuta; Mitsuyoshi Hirokawa; Akira Miyauchi; Ryohei Katoh
Journal:  Endocr Pathol       Date:  2017-06       Impact factor: 3.943

Review 7.  BRAF inhibitors: experience in thyroid cancer and general review of toxicity.

Authors:  M E Cabanillas; A Patel; B P Danysh; R Dadu; S Kopetz; G Falchook
Journal:  Horm Cancer       Date:  2014-12-03       Impact factor: 3.869

8.  Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.

Authors:  Patricia Aragon Han; Hyun-seok Kim; Soonweng Cho; Roghayeh Fazeli; Alireza Najafian; Hunain Khawaja; Melissa McAlexander; Benzon Dy; Meredith Sorensen; Anna Aronova; Thomas J Sebo; Thomas J Giordano; Thomas J Fahey; Geoffrey B Thompson; Paul G Gauger; Helina Somervell; Justin A Bishop; James R Eshleman; Eric B Schneider; Kenneth W Witwer; Christopher B Umbricht; Martha A Zeiger
Journal:  Thyroid       Date:  2016-03-07       Impact factor: 6.568

9.  Predictive Value of BRAFV600E Mutation for Lymph Node Metastasis in Papillary Thyroid Cancer: A Meta-analysis.

Authors:  Jing-Yong Song; Shi-Ran Sun; Fang Dong; Tao Huang; Bin Wu; Jing Zhou
Journal:  Curr Med Sci       Date:  2018-10-20

10.  The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.

Authors:  Agnieszka Czarniecka; Monika Kowal; Dagmara Rusinek; Jolanta Krajewska; Michal Jarzab; Ewa Stobiecka; Ewa Chmielik; Ewa Zembala-Nozynska; Stanislaw Poltorak; Aleksander Sacher; Adam Maciejewski; Jadwiga Zebracka-Gala; Dariusz Lange; Malgorzata Oczko-Wojciechowska; Daria Handkiewicz-Junak; Barbara Jarzab
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.